News from the South African Tuberculosis Vaccine Initiative.
A year in review: SATVI's 2025 Annual Report
SATVI has published its 2025 Annual Report, offering a comprehensive look at the year's research progress, clinical trial milestones and partnerships shaping the global TB vaccine pipeline. Download the full report below to read more.
Read more
Latest Research: A narrative review of the regional prospective observational research in Tuberculosis International Consortium: Sharing diverse data and specimens in the fight against tuberculosis.
Prof M Hatherill has co-authored of "A narrative review of the regional prospective observational research in TB international consortium: sharing diverse data & specimens in the fight against TB" appearing in Clinical Infectious Diseases.
Read more
Opinion piece: The hunt for a new TB vaccine: Why we are now so close, and why it matters.
A/Prof Angelique Luabeya writes in the Spotlight that the world’s only TB vaccine, BCG is over a century old and offers limited protection. South Africa researchers are leading trials of 3 new candidates, signalling a breakthrough.
Read more
Upcoming seminar: Professors Hatherill & Nemes- TB Vaccines & Immunology Seminar, 19 March 2026 (13:00–14:00)
The South African Immunology Society will host a seminar on 19 March where Professors Mark Hatherill and Elisa Nemes will outline the latest advances in TB vaccines and immunology.
Read more
Vacancies
No vacancies found
Previous highlights
Professor Mark Hatherill addresses United Nations High-level Meeting on Tuberculosis
SEPTEMBER 2023: Prof Mark Hatherill, addressed the UN High-level Meeting on Tuberculosis, calling for a quantum jump in TB vaccine research and development (R&D) funding, to deliver the transformative tools needed to end the TB pandemic.
Read more
Phase 1b/2a clinical trial in adults of novel TB vaccine candidate MTBVAC shows promising results.
Findings from the IAVI A-050 study, published in Lancet Global Health, demonstrate that vaccination with MTBVAC caused similar or stronger immune responses compared to the BCG vaccine in adults, of MTBVAC were as safe as BCG.
Read more
Upcoming Events
No upcoming events.